Decompensated Cirrhosis - Market Insight, Epidemiology, and Market Forecast - 2034
Description
Key Highlights
The Decompensated cirrhosis market report provides real-world prescription pattern analysis, emerging drugs assessment, market share, and uptake/adoption pattern of individual therapies, as well as historical and forecasted Decompensated cirrhosis market size from 2020 to 2034 in 7MM. The report also covers current Decompensated cirrhosis treatment practices/algorithms and unmet medical needs to curate the best opportunities and assess the market’s underlying potential.
Geography Covered
Decompensated cirrhosis Overview
Decompensated cirrhosis is the advanced stage of chronic liver disease in which the liver can no longer maintain its essential functions due to extensive fibrosis and structural distortion. It develops when previously compensated cirrhosis progresses, leading to the onset of overt clinical complications such as ascites, variceal bleeding, hepatic encephalopathy, and jaundice.
Cirrhosis usually doesn’t cause any symptoms in its earlier stages. But as it progresses to decompensated cirrhosis, it can cause: Jaundice, Fatigue, Weight loss, Easy bleeding and bruising, Bloated abdomen due to fluid accumulation (ascites), Swollen legs, Confusion, slurred speech, or drowsiness (hepatic encephalopathy), Nausea and loss of appetite, Spider veins, Redness on the palms of the hands, Shrinking testicles and breast growth in men, Unexplained itchiness.
Further details related to country-based variations in diagnosis are provided in the report.
Decompensated Cirrhosis Treatment
Treatment options for decompensated cirrhosis are limited, and reversal of the condition is generally not possible at this advanced stage of liver disease. Candidates with at least one symptom of decompensated cirrhosis and a MELD score of 15 or higher are typically considered for liver transplantation. Transplants may involve either a partial or whole liver from a donor, with the ability of liver tissue to regenerate allowing for partial grafts from living donors; both the transplanted liver and the donor’s liver typically regenerate within a few months. Although liver transplantation offers a potentially life-saving intervention, it is a complex procedure that requires comprehensive evaluation at a transplant center to determine suitability and optimize outcomes.
Further details related to treatment are provided in the report.
Decompensated cirrhosis Epidemiology
The Decompensated cirrhosis epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented as Diagnosed Prevalent Cases of Liver Cirrhosis, Type-specific Diagnosed Prevalent Cases of Liver Cirrhosis, Diagnosed Prevalent Cases of Decompensated Cirrhosis, Gender-specific Diagnosed Prevalent Cases of Decompensated Cirrhosis, and Age-specific Diagnosed Prevalent Cases of Decompensated Cirrhosis in the 7MM, covering the United States, EU4 (Germany, France, Italy, and Spain), and the United Kingdom, and Japan from 2020 to 2034.
The drug chapter segment of the Decompensated Cirrhosis Report encloses a detailed analysis of decompensated cirrhosis marketed drugs and late-stage (Phase III and Phase II) pipeline drugs. It also deep dives into the decompensated cirrhosis pivotal clinical trial details, recent and expected market approvals, patent details, the latest news, and recent deals and collaborations.
Emerging Drugs
ALBUTEIN (albumin): Grifols
In decompensated cirrhosis, albumin is being investigated not just as supportive care but as a disease-modifying therapy aimed at addressing systemic inflammation and circulatory dysfunction that drive complications and organ failure. The Phase III PRECIOSA trial assessed long-term, high-dose albumin in patients with decompensated cirrhosis and ascites, demonstrating reductions in serious complications such as hepatorenal syndrome and spontaneous bacterial peritonitis, along with improved short-term outcomes, although the primary endpoint of one-year transplant-free survival was not met. These results highlight albumin’s potential to alter disease trajectory in decompensated cirrhosis, positioning it as a candidate for long-term therapy subject to further clinical validation.
ALBUTEIN (Human albumin) is already an approved, marketed plasma-derived therapy used in many settings, such as hypovolemia (shock, trauma, burns), cardiopulmonary bypass, acute liver failure, large-volume paracentesis in cirrhosis, and hypoalbuminemia of various causes.
Note: Detailed emerging therapies assessment will be provided in the final report.
Decompensated Cirrhosis Market Outlook
The decompensated cirrhosis market relies on albumin for symptomatic management, which, while effective, does not alter disease progression, highlighting a clear unmet need for disease-modifying therapies. The Phase III PRECIOSA trial showed that long-term, high-dose albumin provided early benefits in transplant-free survival and complication reduction, though it did not meet its primary endpoint, sustaining use in targeted European subgroups without redefining the market. In parallel, Mikrobiomik’s Phase III trial in Spain (EUCT 2023-509151-13-00) evaluating fecal microbiota transplantation (FMT) represents a potential first-in-class approach to modulate the gut-liver axis, reduce infections, and slow progression. Overall, the market is expected to remain stable, anchored by albumin, while emerging interventions like FMT signal opportunities for genuine disease-modifying impact.
Decompensated cirrhosis drug uptake
This section focuses on the uptake rate of potential drugs expected to be launched in the market during 2025–2034, which depends on the competitive landscape, safety, and efficacy data, along with the order of entry. It is important to understand that the key players evaluating their novel therapies in the pivotal and confirmatory trials should remain vigilant when selecting appropriate comparators to stand the greatest chance of a positive opinion from regulatory bodies, leading to approval, smooth launch, and rapid uptake.
Further detailed analysis of emerging therapies' drug uptake in the report…
Decompensated cirrhosis Activities
The report provides insights into different therapeutic candidates in the Phase III and Phase II stages. It also analyzes key players involved in developing targeted therapeutics.
Pipeline Development Activities
The report covers information on collaborations, acquisitions and mergers, licensing, and patent details for Decompensated cirrhosis therapies.
KOL Views
To keep up with the real-world scenario in current and emerging market trends, we take opinions from Key Industry leaders working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts were contacted for insights on the evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, and drug uptake, along with challenges related to accessibility, including Medical/scientific writers, Professors, and Others.
DelveInsight’s analysts connected with 10+ KOLs to gather insights; however, interviews were conducted with 5+ KOLs in the 7MM. Centers such as the National Institute of Allergy and Infectious Diseases, USA, University of Michigan, US, Washington University School of Medicine, US, University Medical Center Hamburg-Eppendorf, US, and University Graduate School of Medicine, US, etc., were contacted. Their opinion helps understand and validate current and emerging therapy treatment patterns or decompensated cirrhosis market trends.
Qualitative Analysis
We perform Qualitative and market Intelligence analysis using various approaches Decompensated cirrhosis, such as SWOT analysis and Conjoint Analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of gaps in disease diagnosis, patient awareness, physician acceptability, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided.
Conjoint Analysis analyzes multiple approved and emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.
In efficacy, the trial’s primary and secondary outcome measures are evaluated; for instance, in event-free survival, one of the most important primary outcome measures is event-free survival and overall survival.
Further, the therapies’ safety is evaluated, wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials. In addition, the scoring is also based on the probability of success and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.
Market Access and Reimbursement
Reimbursement may be referred to as the negotiation of a price between a manufacturer and a payer that allows the manufacturer access to the market. It is provided to reduce the high costs and make the essential drugs affordable. Health technology assessment (HTA) plays an important role in reimbursement decision-making and recommending the use of a drug. These recommendations vary widely throughout the seven major markets, even for the same drug. In the US healthcare system, both Public and Private health insurance coverage are included. Also, Medicare and Medicaid are the largest government-funded programs in the US. The major healthcare programs, including Medicare, Medicaid, Health Insurance Program (CHIP), and the state and federal health insurance marketplaces, are overseen by the Centers for Medicare & Medicaid Services (CMS). Other than these, Pharmacy Benefit Managers (PBMs) and third-party organizations that provide services and educational programs to aid patients are also present.
The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of currently used therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.
Scope of the Report
Please Note: It will take 7-10 business days to complete the report upon order confirmation.
- Decompensated cirrhosis is most prevalent in adults over the age of 50, with a significant increase in patients over the age of 60 due to factors such as chronic alcohol consumption, chronic hepatitis, and metabolic comorbidities.
- Decompensated cirrhosis is an advanced liver disease stage marked by severe fibrosis, significantly impairing liver function and leading to critical complications such as ascites (fluid accumulation in the abdomen), hepatic encephalopathy (neurological disturbances), and oesophageal varices, which can cause dangerous bleeding.
- The complications significantly increase the risk of mortality and often require hospitalisation and evaluation for possible liver transplantation.
- Treatment focuses on symptom management, complication prevention, and addressing the underlying cause, with liver transplantation as the definitive treatment for eligible patients.
- The therapeutic pipeline for decompensated cirrhosis remains limited, with most candidates still in early or mid-stage development and no approved pharmacologic options to alter disease progression.
- The emerging drug pipeline for decompensated cirrhosis includes candidates, such as Albutein (Grifols), and others.
- Mikrobiomik is conducting a Phase III clinical trial in Spain (EUCT number 2023-509151-13-00) to assess the use of Fecal Microbiota Transplantation (FMT) in patients with decompensated cirrhosis.
The Decompensated cirrhosis market report provides real-world prescription pattern analysis, emerging drugs assessment, market share, and uptake/adoption pattern of individual therapies, as well as historical and forecasted Decompensated cirrhosis market size from 2020 to 2034 in 7MM. The report also covers current Decompensated cirrhosis treatment practices/algorithms and unmet medical needs to curate the best opportunities and assess the market’s underlying potential.
Geography Covered
- The United States
- EU4 (Germany, France, Italy, and Spain) and the United Kingdom
- Japan
Decompensated cirrhosis Overview
Decompensated cirrhosis is the advanced stage of chronic liver disease in which the liver can no longer maintain its essential functions due to extensive fibrosis and structural distortion. It develops when previously compensated cirrhosis progresses, leading to the onset of overt clinical complications such as ascites, variceal bleeding, hepatic encephalopathy, and jaundice.
Cirrhosis usually doesn’t cause any symptoms in its earlier stages. But as it progresses to decompensated cirrhosis, it can cause: Jaundice, Fatigue, Weight loss, Easy bleeding and bruising, Bloated abdomen due to fluid accumulation (ascites), Swollen legs, Confusion, slurred speech, or drowsiness (hepatic encephalopathy), Nausea and loss of appetite, Spider veins, Redness on the palms of the hands, Shrinking testicles and breast growth in men, Unexplained itchiness.
Further details related to country-based variations in diagnosis are provided in the report.
Decompensated Cirrhosis Treatment
Treatment options for decompensated cirrhosis are limited, and reversal of the condition is generally not possible at this advanced stage of liver disease. Candidates with at least one symptom of decompensated cirrhosis and a MELD score of 15 or higher are typically considered for liver transplantation. Transplants may involve either a partial or whole liver from a donor, with the ability of liver tissue to regenerate allowing for partial grafts from living donors; both the transplanted liver and the donor’s liver typically regenerate within a few months. Although liver transplantation offers a potentially life-saving intervention, it is a complex procedure that requires comprehensive evaluation at a transplant center to determine suitability and optimize outcomes.
Further details related to treatment are provided in the report.
Decompensated cirrhosis Epidemiology
The Decompensated cirrhosis epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented as Diagnosed Prevalent Cases of Liver Cirrhosis, Type-specific Diagnosed Prevalent Cases of Liver Cirrhosis, Diagnosed Prevalent Cases of Decompensated Cirrhosis, Gender-specific Diagnosed Prevalent Cases of Decompensated Cirrhosis, and Age-specific Diagnosed Prevalent Cases of Decompensated Cirrhosis in the 7MM, covering the United States, EU4 (Germany, France, Italy, and Spain), and the United Kingdom, and Japan from 2020 to 2034.
- In the B, approximately 58.4% of patients had compensated cirrhosis, whereas 41.6% either presented with decompensated cirrhosis at diagnosis or progressed to it over time, reflecting a significant proportion advancing to this severe stage of liver disease.
- Decompensated cirrhosis is observed more frequently in men than in women, reflecting a notable gender disparity in the occurrence of this advanced stage of liver disease, which may be influenced by differences in risk factor exposure, disease progression, and underlying health behaviors.
- In Japan, decompensated cirrhosis cases are predominantly linked to chronic liver diseases, with hepatitis C virus (HCV) infection being the major historical contributor to liver cirrhosis.
- The prevalence of decompensated cirrhosis varies across age groups, with the greatest impact seen in males aged 60–69, who account for about 53.8% of admissions, followed by those aged 50–59, representing approximately 46.2%.
The drug chapter segment of the Decompensated Cirrhosis Report encloses a detailed analysis of decompensated cirrhosis marketed drugs and late-stage (Phase III and Phase II) pipeline drugs. It also deep dives into the decompensated cirrhosis pivotal clinical trial details, recent and expected market approvals, patent details, the latest news, and recent deals and collaborations.
Emerging Drugs
ALBUTEIN (albumin): Grifols
In decompensated cirrhosis, albumin is being investigated not just as supportive care but as a disease-modifying therapy aimed at addressing systemic inflammation and circulatory dysfunction that drive complications and organ failure. The Phase III PRECIOSA trial assessed long-term, high-dose albumin in patients with decompensated cirrhosis and ascites, demonstrating reductions in serious complications such as hepatorenal syndrome and spontaneous bacterial peritonitis, along with improved short-term outcomes, although the primary endpoint of one-year transplant-free survival was not met. These results highlight albumin’s potential to alter disease trajectory in decompensated cirrhosis, positioning it as a candidate for long-term therapy subject to further clinical validation.
ALBUTEIN (Human albumin) is already an approved, marketed plasma-derived therapy used in many settings, such as hypovolemia (shock, trauma, burns), cardiopulmonary bypass, acute liver failure, large-volume paracentesis in cirrhosis, and hypoalbuminemia of various causes.
Note: Detailed emerging therapies assessment will be provided in the final report.
Decompensated Cirrhosis Market Outlook
The decompensated cirrhosis market relies on albumin for symptomatic management, which, while effective, does not alter disease progression, highlighting a clear unmet need for disease-modifying therapies. The Phase III PRECIOSA trial showed that long-term, high-dose albumin provided early benefits in transplant-free survival and complication reduction, though it did not meet its primary endpoint, sustaining use in targeted European subgroups without redefining the market. In parallel, Mikrobiomik’s Phase III trial in Spain (EUCT 2023-509151-13-00) evaluating fecal microbiota transplantation (FMT) represents a potential first-in-class approach to modulate the gut-liver axis, reduce infections, and slow progression. Overall, the market is expected to remain stable, anchored by albumin, while emerging interventions like FMT signal opportunities for genuine disease-modifying impact.
Decompensated cirrhosis drug uptake
This section focuses on the uptake rate of potential drugs expected to be launched in the market during 2025–2034, which depends on the competitive landscape, safety, and efficacy data, along with the order of entry. It is important to understand that the key players evaluating their novel therapies in the pivotal and confirmatory trials should remain vigilant when selecting appropriate comparators to stand the greatest chance of a positive opinion from regulatory bodies, leading to approval, smooth launch, and rapid uptake.
Further detailed analysis of emerging therapies' drug uptake in the report…
Decompensated cirrhosis Activities
The report provides insights into different therapeutic candidates in the Phase III and Phase II stages. It also analyzes key players involved in developing targeted therapeutics.
Pipeline Development Activities
The report covers information on collaborations, acquisitions and mergers, licensing, and patent details for Decompensated cirrhosis therapies.
KOL Views
To keep up with the real-world scenario in current and emerging market trends, we take opinions from Key Industry leaders working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts were contacted for insights on the evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, and drug uptake, along with challenges related to accessibility, including Medical/scientific writers, Professors, and Others.
DelveInsight’s analysts connected with 10+ KOLs to gather insights; however, interviews were conducted with 5+ KOLs in the 7MM. Centers such as the National Institute of Allergy and Infectious Diseases, USA, University of Michigan, US, Washington University School of Medicine, US, University Medical Center Hamburg-Eppendorf, US, and University Graduate School of Medicine, US, etc., were contacted. Their opinion helps understand and validate current and emerging therapy treatment patterns or decompensated cirrhosis market trends.
Qualitative Analysis
We perform Qualitative and market Intelligence analysis using various approaches Decompensated cirrhosis, such as SWOT analysis and Conjoint Analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of gaps in disease diagnosis, patient awareness, physician acceptability, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided.
Conjoint Analysis analyzes multiple approved and emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.
In efficacy, the trial’s primary and secondary outcome measures are evaluated; for instance, in event-free survival, one of the most important primary outcome measures is event-free survival and overall survival.
Further, the therapies’ safety is evaluated, wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials. In addition, the scoring is also based on the probability of success and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.
Market Access and Reimbursement
Reimbursement may be referred to as the negotiation of a price between a manufacturer and a payer that allows the manufacturer access to the market. It is provided to reduce the high costs and make the essential drugs affordable. Health technology assessment (HTA) plays an important role in reimbursement decision-making and recommending the use of a drug. These recommendations vary widely throughout the seven major markets, even for the same drug. In the US healthcare system, both Public and Private health insurance coverage are included. Also, Medicare and Medicaid are the largest government-funded programs in the US. The major healthcare programs, including Medicare, Medicaid, Health Insurance Program (CHIP), and the state and federal health insurance marketplaces, are overseen by the Centers for Medicare & Medicaid Services (CMS). Other than these, Pharmacy Benefit Managers (PBMs) and third-party organizations that provide services and educational programs to aid patients are also present.
The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of currently used therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.
Scope of the Report
- The report covers a segment of key events, an executive summary, a descriptive overview of Decompensated cirrhosis, explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.
- Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression along treatment guidelines.
- Additionally, an all-inclusive account of both the current and emerging therapies, along with the elaborate profiles of late-stage and prominent therapies, will have an impact on the current treatment landscape.
- A detailed review of the decompensated cirrhosis market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
- The report provides an edge while developing business strategies, by understanding trends, through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help in shaping and driving the 7MM Decompensated cirrhosis market.
- Patient Population
- Therapeutic Approach: Decompensated cirrhosis
- Decompensated Cirrhosis Pipeline Analysis
- Decompensated Cirrhosis Market Size and Trends
- Existing and future Market Opportunity
- 10 Years Forecast
- 7MM Coverage
- Decompensated Cirrhosis Epidemiology Segmentation
- Key Cross Competition
- Conjoint analysis
- Drugs Uptake and Key Market Forecast Assumptions
- Current Treatment Practices
- Unmet Needs
- Pipeline Product Profiles
- Market Attractiveness
- Qualitative Analysis (SWOT and Conjoint Analysis)
- What is the historical and forecasted Decompensated cirrhosis patient pool/patient burden in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan?
- Which treatment approach Decompensated cirrhosis will have a significant impact on the Decompensated cirrhosis drug treatment market size?
- How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?
- What are the current and emerging options for the treatment of Decompensated cirrhosis?
- How many companies are developing therapies for the treatment of Decompensated cirrhosis?
- What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitations of existing therapies?
- Patient acceptability in terms of preferred treatment options as per real-world scenarios?
- What are the country-specific accessibility issues of expensive, recently approved therapies?
- The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the decompensated cirrhosis market.
- Insights on patient burden/disease Incidence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
- Understand the existing market opportunities in varying geographies and the growth potential over the coming years.
- Distribution of historical and current patient share based on real-world prescription data along with reported sales of approved products in the US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
- Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
- Detailed analysis and ranking of class-wise potential current and emerging therapies under the conjoint analysis section to provide visibility around leading classes.
- Highlights of access and reimbursement policies of approved therapies, barriers to accessibility of expensive off-label therapies, and patient assistance programs.
- To understand Key Opinion Leaders’ perspectives around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
- Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.
Please Note: It will take 7-10 business days to complete the report upon order confirmation.
Table of Contents
200 Pages
- 1. Key Insights
- 2. Report Introduction
- 3. Executive Summary of Decompensated Cirrhosis
- 4. Key Events
- 5. Epidemiology and Market Forecast Methodology of Decompensated Cirrhosis
- 6. Decompensated Cirrhosis Market Overview at a Glance in the 7MM
- 6.1. Market Share (%) Distribution by Therapies in 2024
- 6.2. Market Share (%) Distribution by Therapies in 2034
- 7. Decompensated cirrhosis: Background and Overview
- 8. Epidemiology and Patient Population of Decompensated Cirrhosis in the 7MM
- 8.1. Key Findings
- 8.2. Assumptions and Rationale
- 8.3. Total prevalent cases of Decompensated Cirrhosis in the 7MM
- 8.4. The United States
- 8.4.1. Diagnosed prevalent cases of Liver Cirrhosis in the United States
- 8.4.2. Type-specific diagnosed prevalent cases of Liver cirrhosis in the United States
- 8.4.3. Diagnosed prevalent cases of Decompensated Cirrhosis in the United States
- 8.4.4. Gender-specific diagnosed prevalent cases of Decompensated cirrhosis in the United States
- 8.4.5. Age-specific diagnosed prevalent cases of Decompensated cirrhosis in the United States
- 8.5. EU4 and the UK
- 8.5.1. Diagnosed prevalent cases of Liver cirrhosis in the EU4 and the UK
- 8.5.2. Type-specific diagnosed prevalent cases of Liver cirrhosis in the EU4 and the UK
- 8.5.3. Diagnosed prevalent cases of Decompensated Cirrhosis in the EU4 and the UK
- 8.5.4. Gender-specific diagnosed prevalent cases of Decompensated cirrhosis in the EU4 and the UK
- 8.5.5. Age-specific diagnosed prevalent cases of Decompensated cirrhosis in the EU4 and the UK
- 8.6. Japan
- 8.6.1. Diagnosed prevalent cases of Liver cirrhosis in Japan
- 8.6.2. Type-specific diagnosed prevalent cases of Liver cirrhosis in Japan
- 8.6.3. Diagnosed prevalent cases of Decompensated Cirrhosis in Japan
- 8.6.4. Gender-specific diagnosed prevalent cases of Decompensated cirrhosis in Japan
- 8.6.5. Age-specific diagnosed prevalent cases of Decompensated cirrhosis in Japan
- List to be continued in the final report…
- 9. Emerging Therapies of Decompensated Cirrhosis
- 9.1. Key Competitors
- 9.3. ALBUTEIN (albumin): Grifols
- 9.3.1 . Product Description
- 9.3.2. Other Developmental Activities
- 9.3.3 . Clinical Development
- 9.3.3.1. Clinical Trial Information
- 9.3.4 . Safety and Efficacy
- 9.3.5. Analyst Views
- List to be continued in the final report…
- 10. Decompensated Cirrhosis: Seven Major Market Analysis
- 10.1. Key Findings
- 10.2. Market Outlook of Decompensated Cirrhosis
- 10.3. Conjoint Analysis of Decompensated Cirrhosis
- 10.4. Key Market Forecast Assumptions of Decompensated Cirrhosis
- 10.4.1. Cost Assumptions and Rebates
- 10.4.2. Pricing Trends
- 10.4.3. Analogue Assessment
- 10.4.4. Launch Year and Therapy Uptakes
- 10.5. Total Market Size of Decompensated Cirrhosis in the 7MM
- 10.6. Market Size of Decompensated Cirrhosis by Indication in the 7MM
- 10.7. The United States Market Size
- 10.7.1 . Total Market Size of Decompensated Cirrhosis in the United States
- 10.7.2. Market Size of Decompensated Cirrhosis by Indication in the United States
- 10.7.3. Market Size of Decompensated Cirrhosis by Therapies in the United States
- 10.8. EU4 and the UK Market Size
- 10.8.1. Total Market Size of Decompensated Cirrhosis in EU4 and the UK
- 10.8.2. Market Size of Decompensated Cirrhosis by Indication in EU4 and the UK
- 10.8.3. Market Size of Decompensated Cirrhosis by Therapies in EU4 and the UK
- 10.9. Japan Market Size
- 10.9.1 . Total Market Size of Decompensated Cirrhosis in Japan
- 10.9.2. Market Size of Decompensated Cirrhosis by Indication in Japan
- 10.9.3. Market Size of Decompensated Cirrhosis by Therapies in Japan
- 11. Market Access and Reimbursement of Decompensated Cirrhosis
- 12. SWOT Analysis of Decompensated Cirrhosis
- 13. KOL Views of Decompensated Cirrhosis
- 14. Unmet Needs of Decompensated Cirrhosis
- 15. Appendix
- 15.1. Bibliography
- 15.2. Report Methodology
- 16. DelveInsight Capabilities
- 17. Disclaimer
- 18. About DelveInsight
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
